Latest / The Dales Report | Trade to Black
Why This Quarter Could Be Vital for Cybin's FDA Milestones! | TDR Exclusive
Welcome to our latest TDR exclusive! In this episode with Doug Drysdale, CEO of Cybin we get into their groundbreaking developments in mental healthcare, including FDA clearance for a Phase 2a study of CYB004 in Generalized Anxiety Disorder, the positive impact of CYB003 on MADRS scores, and the future of psychedelic therapies in the industry. Stay tuned for exclusive insights into the evolving landscape of mental health treatments and Cybin's mission to revolutionize the field. Guest: Doug Drysdale, CEO of Cybin 🔥 Join us for an in-depth interview with Cybin Inc., where we explore…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.